Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PTEN tumor suppressor gene is frequently mutated in type I endometrial cancers and this mutation results in hyperactivation of the PI3K/AKT pathway.
|
22911820 |
2012 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Focusing on ARID1A, we integrated mutation profiles with functional proteomics in 222 endometrial cancer samples, demonstrating that ARID1A mutations frequently co-occur with mutations in the phosphatidylinositol 3-kinase (PI3K) pathway and are associated with PI3K pathway activation. siRNA knockdown in endometrial cancer cell lines increased AKT phosphorylation supporting ARID1A as a novel regulator of PI3K pathway activity.
|
23028188 |
2012 |
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
E2 stimulated cell proliferation and induced GPR30 expression and PI3K/Akt pathway activation in endometrial cancer cells, Ishikawa cells, and HEC-1A cells, whereas the expression of ERs remained unchangeable.
|
23235274 |
2013 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present a rationale for investigating ER-α's potential to predict response to PI3K/mTOR inhibitors in clinical trials and also suggest EMT inhibitors to ER-α-negative endometrial carcinomas.
|
23319822 |
2013 |
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.
|
23538402 |
2013 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
|
23674493 |
2013 |
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analyzed the expression of ARID1A in 146 endometrial cancers (130 EECs and 16 non-EECs) in relation to alterations in the PI3K-Akt pathway (PTEN expression/KRAS/PIK3CA mutations), TP53 status (TP53 immunohistochemistry) and microsatellite instability.
|
23702729 |
2013 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This crosstalk could be taken into account in developing novel therapeutic methods by targeting the ERα and PI3K/AKT/mTOR pathways in endometrial carcinoma.
|
24366110 |
2014 |
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Alterations in the PI3K pathway are prevalent in endometrial cancer due to PIK3CA mutation and loss of PTEN.
|
24561032 |
2014 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K/mammalian target of rapamycin (mTOR) pathway aberrations occur in 40% to 80% of endometrial cancer.
|
24651628 |
2014 |
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.
|
24995579 |
2014 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting key signaling components of PI3K/AKT pathway by restoring or inhibiting miRNA function holds promise as a potential therapeutic approach to suppress EMT and CSC in endometrial cancer.
|
25141911 |
2014 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC).
|
25624430 |
2015 |
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas.
|
25701704 |
2015 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings support the de-regulation of the PI3K/Akt/mTOR and MAPK signaling pathways in type I endometrial carcinomas suggesting involvement of these pivotal pathways in endometrial carcinogenesis.
|
25862896 |
2015 |
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We sought to determine the impact of PI3K pathway alterations on progression free survival in a cohort of endometrioid endometrial cancers.
|
26045339 |
2015 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of PI3K/Akt signaling reversed the enhanced cell growth in Nedd4-overexpressing endometrial cancer cells.
|
26193427 |
2015 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIF1A, NF-kB and PI3K/mTOR might be potential treatment targets in aggressive endometrial cancers with presence of tumor necrosis.
|
26485755 |
2015 |
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of an endometrial cancer risk allele within a member of the PI3K/AKT signaling pathway, more commonly activated in tumors by somatic alterations, raises the possibility that well tolerated inhibitors targeting this pathway could be candidates for evaluation as chemopreventive agents in individuals at high risk of developing endometrial cancer.
|
27259051 |
2016 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed that the clinical behaviour of endometrial cancers as a group was associated with hormone receptor signalling, PI3K pathway signalling and DNA mismatch repair processes.
|
27420608 |
2016 |
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have shown that activation of the PI3K-protein kinase B (Akt) signaling pathway has important effects on insulin resistance and endometrial cancer.
|
27613818 |
2017 |
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PI3K/PTEN/AKT pathway is the most frequently mutated pathway in endometrial carcinoma.
|
27910071 |
2017 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings suggest that PIK3CB/p110β contributes to some of the pleiotropic functions of PI3K in endometrial cancer, particularly in the early steps by contributing to cell proliferation.
|
28002804 |
2017 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of the PI3K pathway is seen in more than 90% of FGFR2<sup>mutant</sup> endometrial cancers.
|
28119489 |
2017 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapeutic targeting of the PI3K pathway is an active area of research in multiple cancer types, including breast and endometrial cancers.
|
28184015 |
2017 |